Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Studied

Randomized safety trial comparing oral semaglutide with placebo for cardiovascular death, nonfatal heart attack or stroke.

Who / model

3183 people with type 2 diabetes at high cardiovascular risk; median time in the trial was 15.9 months.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Primary cardiovascular events occurred in 3.8% versus 4.8%, meeting the trial's safety criterion. Cardiovascular deaths were 0.9% versus 1.9%; nonfatal heart attacks were 2.3% versus 1.9%, and nonfatal strokes 0.8% versus 1.0%. Digestive adverse events led to more treatment discontinuations with oral semaglutide.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary